,					
Form PTO-14 (REV. 8-83)		artment of Commerce d Trademark Office	Atty. Docket: 0264724-0007	In re Appl 09/193,89	lication No. 2
SUPPLE	MENTAL INFORMATION STATEME	ΓΙΟΝ	Applicant: Fogel		
(Use several sheets if necessary)		Filing Date: November 18, 1998 Group: 1614		1614	
		U. S. PATENT DOCU	MENTS		
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
/Y.C./	4,122,193	Scherm et al.	October 24, 1978		
/Y.C./	4,233,229	Chakrabarti	November 11, 1980	HOH	₽E 0
/Y.C./	4,355,043	Durlach	October 19, 1982	L Z	30
/Y.C./	5,061,703	Bormann et al.	October 29, 1991	5	
/Y.C./	5,262,162	Bormann et al.	November 16, 1993	600/290	VED
/Y.C./	5,382,601	Nürnberg et al.	January 17, 1995	0	
/Y.C./	5,455,279	Lipton	October 3, 1995		
/Y.C./	5,602,150	Lidsky	February 11, 1997		
/Y.C./	5,614,560	Lipton	March 25, 1997		
	FO	OREIGN PATENT DOO	CUMENTS		
Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No
				•	
Examiner's Initials	(I)	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/Y.C./		Alexander, et al., "Serum Calcium and Magnesium in Schizophrenia: Relationship to Clinical Phenomena and Neuroleptic Treatment", Brit. F. Psychiat. 133: 143-49, 1978.			

Ananth, et al., "Meige's Syndrome Associated with Neuroleptic Treatment", Am J. Psychiatry 145:4, April, 1988.

/Y.C./

m PTO-144 EV. 8-83)	Department of Commerce Patent and Trademark Office	Atty. Decket: 0264724-0007	In re Application No. 09/193,892	
SUPPLEMENTATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Fogel		
		Filing Date: November 18, 1998	Group: 1623 2001	
/Y.C./	Andrew, "Clinical Relationship of Extrapyrar Can. J. Psych., 39:576-580, 1994.	nidal Symptoms and T	ardive Dyskinesia",	
/Y.C./	Andreassen, et al., "Tardive Dyskinesia: Behavorial Effects of Repeated Intracerebroventricular Haloperidol Injections in Rats Do Not Confirm the Kindling Hypothesis", Pharmacology Biochemistry and Behavior, 49:2, 309-312, 1994			
/Y.C./	Andreassen, et al., "Inhibition by Memantine of the Development of Persistant Oral Dyskinesias Induced by Long-Term Haloperidol Treatment of Rats", British Journal of Pharmacology 119: 751-757, 1996.			
/Y.C./	Arthurs, et al., "Treatment of Blepharospasm with Medication, Surgery and Type A Botulinum Toxin", Can J. Ophthalmol, 22:1, 1987.			
/Y.C./	Athanassenas, et al., "Serum Calcium and Magnesium Levels in Chronic Schizophrenics", Journal of Clinical Psychopharmacology, 3:4, August, 1983			
/Y.C./	Bezchilbynk-Butler et al., "Antiparkinsonian Drugs in the Treatment of Neuroleptic-Induced Extrapyramidal Symptoms", Can. J. Psych., 39:74-84, 1994.			
/Y.C./	Boumans et al., "Is the Social Acceptability of Psychiatric Patients Decreased by Orofacial Dyskinesia?", Schizo Bull, 20:339-344, 1994.			
/Y.C./	Britton, et al., "Dextromethorphan Protects Against Cerebral Injury Following Transient, But Not Permanent, Focal Ischemia in Rats" Life Sciences, 60:20, 1729-1740, 1997.			
/Y.C./	Büchel et al., "Oral Tardive Dyskinesia: Validation of a Measuring Device Using Digital Image Processing", Psychopharmacology-Berl, 117:162-165, 1995.			
/Y.C./	Casey, D. "Pharmacology of Blepharospasm-Oromandibular Dystonia Syndrome", Neurology, 30:690-695, July, 1980.			
/Y.C./	Cassady, et al., "Neuroleptic Induced Movement Disorders", Cambridge, England: Cambridge University Press, 1997, pp454-469.			
/Y.C./	Chabenat, et al., "Physicochemical, Pharmacological and Pharmacokinetic Study of a New GABAerigic Compound, Calcium Acetylhomotaurinate", Methods Find Exp Clin Pharmacol, 10:311-7, 1988 May.			
/Y.C./	1	Chakos et al., "Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia", Arch Gen Psychiatry, 53:313-319, 1996.		
/Y.C./	Chappell, et al., "Future Therapies of Touret America, 15:2, May, 1997.	te Syndrome", Neurole	ogic Clinics of North	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Chen, et al., "Focal Dystonia and Repetitive Related Research". 351: 102-106.	Motion Disorders", C	inical Orthopaedico and	

Form PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	Atty. Socket: 0264724-0007 Applicant: Fogel	In re Application No. 709/193,895 OCT	
II -	MENTAL INFORMATION LOSURE STATEMENT SP 2 8 2000		3 2007 ER 1600/	
(Use s	everal sheets if necessary)	Filing Date: November 18, 1998	Group: 1618	
/Y.C./	Dabiri, et al., "Effectiveness of Vitamin E for Treatment of Long-Term Tardive Dyskinesia", Am J. Psychiatry 151:6, June 1994.			
/Y.C./	Decker et al., "Amantadine Hydrochloride Treatment of Tardive Dyskinesia", October 7, New England J. Med, 285:860, 1971.			
/Y.C./	Delfs et al., "Expression of Glutamic Acid Decarboxylase mRNA in Striatum and Pallidum in an Animal Model of Tardive Dyskinesia", Exp. Neurol, 133:175-188, 1995.			
/Y.C./	De Mattos, et al., "Distonias Aspectos Clinicose E Terapeuticos EM 64 Pacientes", Arq. Neuropsiquiatr, 54:30-36, 1996.			
/Y.C./	Dimpfel, "Effects of Memantine on Synaptic Transmission in the Hippocampus in Vitro", Arzneimittelforschung, 45:1-5, 1995.			
/Y.C./	Durlach, et al., "Magnesium Status and Ageing: An Update", Magnesium Research 11:25-42, 1997.			
/Y.C./	Egan M.F., et al., "Treatment of Tardive Dyskinesia" Schizophr Bull, 23(4):583-609 1997			
/Y.C./	Elston, J. "The Management of Blepharospasm and Hemifacial Spasm", J. Neurol 239:5-8, 1992.			
/Y.C./	Ema, et al., "Alcohol-Induced Vascular Damage of Brain is Ameliorated by Administration of Magnesium", Alcohol, 15:95-103, 1998.			
/Y.C./	Erdo et al., "Memantine is Highly Potent in Protecting Cortical Cultures against Excitotoxic Cell Death Evoked by Glutamate and N-Methyl-D-Aspartate", Eur. J. Pharmacol, 198:215-217, 1991.			
/Y.C./	Esper, et al., "Adult-Onset Focal Dystonias: Presentation and Treatment Options", Tennessee Medicine, 18-20, January, 1997.			
/Y.C./	Fariello, R.G. et al., "Homotaurine (3 Aminopropanesulfonic Acid; 3APS) Protects Froom The Convulsant and Cytotoxic Effect of Systemically Adminstered Kainic Acid." Neurology, 32:241-5, March, 1982.			
/Y.C./	Galardi, et al., "Basal Ganglia and Thalamo-Cortical Hypermetabolism in Patients with Spasmodic Torticollis", Acta Neurol Scand 94:172-176, 1996.			
	Greensmith, et al., "Magnesium Ions Reduce A Exposure to N-Methyl-p-Aspartate In The Deve		owing Norvo Injury or	
/Y.C./	Gao et al., "Tiagabine Inhibits Haloperidol-Induced Oral Dyskinesias in Rats", J. Neural Transmission, 95:63-69, 1994.			
/Y.C./	Gardos, et al., "The Treatment of Tardive Dyskinesias", Psychopharmacology, 1503-1511			

1995.

		U.S. Department of Commerce Patent and Trademark Office ENTAL INFORMATION OSURE STATEMENT SP 2 8 200	Atty. Docket: 0264724-0007 Applicant: Fogel	In re Application No. 09/193,892 CENTER 1800 CT 0.3	
	(Use se	veral sheets if necessary)	Filing Date: November 18, 1998	Group: 16 民 二 C C C C C C C C C C	
Gullestad, et al., "Magnesium Status in Healthy Free Living Elderly Norweg of the American College of Nutrition. 13:1.45-50.				Norwegians", Journal	
Hallett, M. "The Neurophysiology of Dystonia", Arch Neurol, 55: May, 1 /Y.C./ Hayashi et al., "Prevalence of and Risk Factors for Respiratory Dyskinesia Neuropharmacol, 19:390-398, 1996. /Y.C./ Holds, et al., "Facial Dystonia, Essential Blepharospasm and Hemifacial Sp. 43(6): 2113-2120, June, 1991. /Y.C./ Imamura et al., "Improved Preseveration with Amantadine", Abstract, No-46:556-562, 1994. /Y.C./ Jacoby, et al., "Diltiazem Reduces the Contractility of Extraocular Muscles Vivo", Investigative Ophthalmology & Visual Science, 31:569-576, March Double-Blind Crossover Study", Ann Neurol 11:41-47, 1982. /Y.C./ Jankovic, J. "Treatment of Hyperkinetic Movement Disorders with Tetrabe Double-Blind Crossover Study", Ann Neurol 11:41-47, 1982. /Y.C./ Jankovic, J. "Blepharospasm and Orofacial - Cervical Dystonia: Clinical ar Pharmacological Findings in 100 Patients", Ann Neurol 13:402-411, 1983.			", Arch Neurol, 55: M	ſay, 1998	
			for Respiratory Dysk	inesia", Clin.	
			arospasm and Hemifac	cial Spasm", AFP,	
			Amantadine", Abstract	t, No-To-Shinkei,	
			uscles in Vitro and in March, 1990.		
			etrabenazine: A		
			cal and 1983.		
Jeste et al., "Risk of Tardive Dyskinesia in Older Patients. Study of 266 Outpatients", Arch Gen Psychiatry, 52:756-7		ler Patients. A Prospe y, 52:756-765, 1995.	A Prospective Longitudinal , 1995.		
	/Y.C./	Keilhoff et al., "Memantine Prevents Quinolinic Acid-Induced Hippocampal Damage", Eur. J. Pharmacol, 219:451-454, 1992.			
Kirov, et al., "Plasma Magnesium Levels in a Population of Psychiatric Patients: Correlations with Symptoms", Neuropsychobiology 30:73-78, 1994. Y.C. Kornhuber et al., "New Therapeutic Possibilities with Low-Affinity NMDA Recent Antagonists", Abstract, Nervenarzt, 67:77-82, 1996.		Kirov, et al., "Plasma Magnesium Levels in a Correlations with Symptoms", Neuropsychobio	na Magnesium Levels in a Population of Psychiatric Patients: ymptoms", Neuropsychobiology 30:73-78, 1994.		
		NMDA Receptor			
000000	000000000000000000000000000000000000000	Krielglstein, et al., "Apparent Independent Act	ion of Nimodipine and		
*****	Antagonists to Protect Cultured Neurons Against Glutamate-Induced Damage				
Kurata, et al., "Meige's Syndrome During Long-Term Neuroleptic Treatment", Japanese Journal of Psychiatry" 43: 627-631, 1989.			reatment", The		
Kurlan, R. "Treatment of Tics", Neurologic Clinics of North Ame May, 1997.		linics of North Americ	erica, 15:2, 403-409,		
	/Y.C./	Lam et al., "Vitamin E in the Treatment of Tardive Dyskinesia: A Replication Study, J. Nerv. Ment Dis, 182:113-114, 1994.			

Latimer, "Tardive Dyskinesia: A Review", Abstract, Can J. Psych, 40:S49-54, 1995.

/Y.C./

Form PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 0264724-0007	In re Applicat No. 09/193,892	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) (Use Several sheets if necessary)		Applicant: Fogel		
		Filing Date: November 18, 1998	Group: 161765	
/Y.C./	Leckman, et al., "Tic Disorders", The Psychiatric Clinics of North America, 20:4 839-861, December, 1997.			
/Y.C./	Lichter, et al., "Predictors of Clonidine Response in Tourette Syndrome: Implications and Inferences", Journal of Child Neurology 11:93-97, March, 1996.			
/Y.C./	Lipski, et al., "A Study of Nutritional Deficits of Long-Stay Geriatric Patients, Age and Agening 22:244-255, 1993.			
/Y.C./	Lohr et al., "A Double-Blind Placebo-Controlled Study of Vitamin E Treatment of Tardive Dyskinesia", J. Clin. Psychiatry, 57:167-173, 1996.			
	Lombardini, John B. "Opposite Effects of 2-Aminoethanesulfonic Acid (Taurine) and			
000000000000000000000000000000000000000	Aminomethanesulfonic Acid on Calcium Ion Uptake in Rat Retinal Preparations"			
/Y.C./	Martin, et al., "Comparison of Inorganic Elements from Autopsy Tissue of Young and Elderly Subjects", J. Trace Elem. Electrolytes Health Dis.,5:203-211, 1991.			
/Y.C _: /	Mauriello, et al., "Treatment Selections of 239 Patients with Blepharospasm and Meige Syndrome over 11 Years", Br. J. Ophthamaol, 80(12):1073-1076, December, 1996			
/Y.C./	Mauriello, et al., "Treatment Choices of 119 Patients with Hemifacial Spasm over 11 Years", Clinical Neurology and Neurosurgery, 98: 213-216, August 1996.			
/Y.C./	Meshul, et al., "Correlation of Vacuous Chewing Movements with Morphological Changes in Rats Following 1-Year Treatment with Haloperidol", Psychopharmacology 125:238-247, 1996			
	Micheli, et al., "Continuous Dopaminergic S	timulation in Cranial Dy	vstonia" Clinical	
000000000000000000000000000000000000000	Neuropharmacology, 11·3, 241-249	000000000000000000000000000000000000000	000000000000000000000000000000000000000	
/Y.C./	Muller et al., "Noncompetitive NMDA Receptor Antagonists with Fast Open-Channel Blocking Kinetics and Strong Voltage-Dependency as Potential Therapeutic Agents for Alzheimer's Dementia", Pharmacopsychiatry, 28:113-124, 1995.			
/Y.C./	Pahl et al., "Positron-Emission Tomography in Tardive Dyskinesia", J. Neuropsych Clin. Neurosci, 7:457-465, 1995.			
/Y.C./	Panula-Lehto E. et al., "Effects of Taurine, Homotaurine and GABA on Hypothalamic and Striataldopamine Metabolism." Naunyn Schmiedebergs Arch Pharmacol, 346:57-62, July, 1992			
/Y.C./	Perlmutter, et al., "Decreased [18F] Spiperone Binding in Putamen Idiopathic Focal Dystonia", The Journal of Neuroscience, 17:843-850, 1997.			
/Y.C./	Ploceniak, "Bruxisme et magnesium, mon experience clinique depuis 1980" Communications Libres, 91, suppII, 1990			

	Patent and Trademark Office ENTAL INFORMATION OSUBE STATEMENT	Atty. Docket: 0264724-0007 Applicant: Fogel	In re Application No. 09/193,892 CENTER 160		
•	veral sheets if necessary)	Filing Date: November 18, 1998	Group: 16128		
/Y.C./	Raja, "The Treatment of Tardive Dyskinesia", Abstract, Schweiz Arch Neurol Psychaitr, 47: 1996.				
, /Y.C./	Ransmayr, et al., "Pharmacological Study in Meige's Syndrome with Predominant Blepharospasm", Clinical Neuropharmacology", 11:68-76, 1988.				
/Y.C./	Rouhani, S. et al., "Effects of Muscimol or Homotaurine on Sleep-Wake States in Alcohol-dependent rats during Withdrawal." Pharmacol Biochem Behav, 59:955-60, April, 1998				
/Y.C./	Sachdev, "Blinking-blepharospasm after long-term neuroleptic treatment", The Medical Journal of Australia, 150:341-343, March 20, 1989				
/Y.C./	Sachdev et al., "Negative Symptoms, Cognitive Dysfunction, Tardive Akathisia and Tardive Dyskinesia", Acta Psychiatr Scand, 93:451-459, 1996.				
/Y.C./	Sanberg, et al., "Nicotine for the Treatment of Tourette's Syndrome", Pharmacol. Ther. Vol. 74, 21-25, 1997.				
/Y.C./	Sandyk, "Blepharospasm - Successful Treatment with Baclofen and Sodium Valproate", SA Medical Journal, 64:3 December, 1993.				
/Y.C./	Sano et al., "A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease", The New England Journal of Medicine, Vol. 336, No. 17, pp. 1216-1247, April 24, 1997.				
/Y.C./	Scahill, et al., "Fluoxetine Has No Marked Effect on Tic Symptoms in Patients with Tourette's Syndrome: A Double-Blind Placebo-Controlled Study," Journal of Child and Adolescent Psychopharmacology, 7:75-85, 1997.				
/Y.C./	Schulz et al., "Neuroprotective Strategies for Treatment of Lesions Produced by Mitochondrial Toxins: Implications for Neurodegenerative Diseases", Neuroscience, 71:1043-1048, 1996.				
/Y.C./	Shane, et al., "Magnesium Deficiency in Alcohol Addiction and Withdrawal", Magnes Trace Elem, 92:263-268, 1991.				
/Y.C./	Silver et al., "No Difference in the Effect of Biperiden and Amantadine on Parkinsonian- and Tardive Dyskinesia-type Involuntary Movements: A Double-Blind Crossover, Placebo- Controlled Study in Medicated Chronic Schizophrenic Patients", Abstract, J. Clin. Psychiatry, 56:167-170, 1995.				
/Y.C./	Silver, et al., "Case Study: Long-Term Potentiation of Neuroleptics with Transdermal Nicotine in Tourette's Syndrome, J. Am. Chil. Adolesc. Psychiatry, 35:12, December, 1996				
/Y.C./	Stoessl, "Effects of Ethanol in a Putative Rode Biochem Behav, 54:541-546, 1996.	ent Model of Tardive I	Dyskinesia", Pharmacol		

	Patent and Trademark Office ENTAL INFORMATION	Atty. Docket: 0264724-0007 Applicant: Fogel	In re Application No. 09/193,892 H
-	veral sheets if necessary) SEP 2 8 2001 PRADEMAN	Filing Date: November 18, 1998	Group: 164 = 1
. /Y.C./	Steingard, "Adjunctive Clonazepam Treatment Tic Disorders and ADHD, J. Am. Acad. Child 1994		
· /Y.C./	Swartz, "Tardive Psychopathology", Neuropsychobiology, 43:115-119, 1995.		
/Y.C./	Tirelli et al., "Differential Effects of Direct and Indirect Dopamine Agonists on the Induction of Gnawing in C57B1/6J Mice", J. Pharmacol Exp. Ther., 273:7-15, 1995.		
/Y.C./	Trube, et al., "Dextromethorphan: Cellular Effects Reducing Neuronal Hyperactivity" Epilepsia. 35:5 S62-S67, 1994		
/Y.C./	Tsai, et al., "Markers of Glutamatergic Neurotransmission and Oxidative Stress Associated with Tardive Dyskinesia", Am J. Psychiatry 155:9, September, 1998.		
/Y.C./	Vale et al., "Amantadine for Dyskinesia Tarda", New Eng. J. Med., 284:673, 1971.		
/Y.C./	Van-Rekum et al., "N of 1 Study: Amantadine for the Amotivational Syndrome in a Patient with Traumatic Brain Injury", Brian Inj. 9:49-53, 1995.		
/Y.C./	Waddington et al., "Cognitive Dysfunction in Chronic Schizophrenia Followed Prospectively Over 10 Years and Its Longitudinal Relationship to the Emergence of Tardive Dyskinesia", Psychol Med, 26:681-688, 1996.		
/Y.C./	Wenk et al., "MK-801, Memantine and Amantadine Show Neuroprotective Activity in the Nucleus Basalis Magnocellularis", Eur. J. Pharmacol, 293:267-270, 1995.		
/Y.C./	Wilde, et al., "Acamprosate", Adis Drug Evaluation, 53:1038-1053, June, 1997.		
/Y.C./	Yassa, et al., "Plasma Magnesium in Chronic Schizophrenia", Int. Pharmacopsychiat. 14:57-64 (1979)		
/Y.C./	Ziemann, et al., "Decreased Motor Inhibition in Tourette's Disorder: Evidence From Transcranial Magnetic Stimulation", Am J Psychiatry, 154:1277-1284, 1997.		
FYAMINED	/Yong Chong/	DATE CONSIDER	FD 07/18/2008

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.